Related Experiment Videos
Diffusion and binding of monoclonal antibody TNT-1 in multicellular tumor spheroids
F M Cheng1, E B Hansen, C R Taylor
1Department of Diagnostic Radiology, City of Hope National Medical Center, Duarte, CA 91010-0269.
Abstract:
Tumor spheroids of HT-29 human colon adenocarcinoma and A375 melanoma were established to investigate the uptake and clearance kinetics of TNT-1, a monoclonal antibody that targets necrotic cells of tumors. Our data reveal that there was rapid uptake of TNT-1 and its F(ab')2 fragment in both spheroid models, whereas an antibody of irrelevant specificity, Lym-1, and its F(ab')2 fragment bound poorly to the spheroids. Unlike previously reported monoclonal antibodies to tumor cell-surface antigens, TNT-1 showed 1) a linear uptake that increased over time without saturation in tumor spheroids and 2) an unexpected uptake by a subpopulation of cells in the viable outer rim of the spheroids. These preclinical studies provide important information concerning the therapeutic potential of TNT monoclonal antibodies for the treatment of cancer and micrometastases.
Insights
The monoclonal antibody TNT-1 rapidly enters tumor spheroids, showing linear uptake and targeting necrotic cells. This antibody demonstrates therapeutic potential for cancer and micrometastasis treatment.
Area of Science:
- Oncology
- Immunology
- Pharmacokinetics
Background:
- Monoclonal antibodies (mAbs) are crucial in targeted cancer therapy.
- Understanding antibody uptake and distribution within tumors is vital for efficacy.
- TNT-1 targets necrotic tumor cells, a distinct therapeutic strategy.
Purpose of the Study:
- To investigate the uptake and clearance kinetics of TNT-1 and its F(ab')2 fragment in tumor spheroid models.
- To compare TNT-1's binding characteristics with an irrelevant antibody (Lym-1).
- To evaluate the therapeutic potential of TNT-1 for cancer and micrometastases.
Main Methods:
- Establishment of HT-29 colon adenocarcinoma and A375 melanoma tumor spheroids.
- In vitro assessment of TNT-1 and Lym-1 (and their F(ab')2 fragments) uptake and binding.
- Kinetic analysis of antibody distribution within spheroid models.
Main Results:
- Rapid uptake of TNT-1 and its F(ab')2 fragment was observed in both spheroid models.
- Lym-1 and its F(ab')2 fragment showed poor binding to the spheroids.
- TNT-1 exhibited linear uptake over time without saturation and unexpected uptake in viable cells at the spheroid rim.
Conclusions:
- TNT-1 demonstrates efficient uptake in tumor spheroids, targeting necrotic cells.
- The unique uptake kinetics suggest potential for treating solid tumors and micrometastases.
- These findings support the therapeutic promise of TNT monoclonal antibodies.